- Home
- PHUN vs ADAG Comparison
PHUN vs ADAG Comparison
Compare PHUN & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- ADAG
- Stock Information
- Founded
- PHUN 2009
- ADAG 2011
- Country
- PHUN United States
- ADAG China
- Employees
- PHUN N/A
- ADAG N/A
- Industry
- PHUN EDP Services
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- ADAG Health Care
- Exchange
- PHUN Nasdaq
- ADAG Nasdaq
- Market Cap
- PHUN 64.1M
- ADAG 91.4M
- IPO Year
- PHUN N/A
- ADAG 2021
- Fundamental
- Price
- PHUN $3.44
- ADAG $1.88
- Analyst Decision
- PHUN Buy
- ADAG Strong Buy
- Analyst Count
- PHUN 2
- ADAG 1
- Target Price
- PHUN $7.75
- ADAG $8.00
- AVG Volume (30 Days)
- PHUN 360.4K
- ADAG 92.2K
- Earning Date
- PHUN 08-07-2025
- ADAG 07-24-2025
- Dividend Yield
- PHUN N/A
- ADAG N/A
- EPS Growth
- PHUN N/A
- ADAG N/A
- EPS
- PHUN N/A
- ADAG N/A
- Revenue
- PHUN $2,956,000.00
- ADAG $103,204.00
- Revenue This Year
- PHUN $3.01
- ADAG $6,488.89
- Revenue Next Year
- PHUN $50.72
- ADAG $57.50
- P/E Ratio
- PHUN N/A
- ADAG N/A
- Revenue Growth
- PHUN N/A
- ADAG N/A
- 52 Week Low
- PHUN $2.22
- ADAG $1.33
- 52 Week High
- PHUN $14.60
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- PHUN 60.41
- ADAG 44.87
- Support Level
- PHUN $2.95
- ADAG $1.74
- Resistance Level
- PHUN $3.10
- ADAG $2.10
- Average True Range (ATR)
- PHUN 0.17
- ADAG 0.10
- MACD
- PHUN 0.03
- ADAG -0.02
- Stochastic Oscillator
- PHUN 93.65
- ADAG 16.67
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.